A large-scale study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups.

Mdxhealth (MDXH) announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score, GPS, testing in the landmark UK ProtecT trial. This study ...

Researchers will test whether the company's Genomic Prostate Score assay predicts disease progression and outcomes in a prospective cohort.

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized ...

Cancer is a disease that starts with uncontrolled cell division and eventually causes tissue and organ damage. The disease ...

Prostate cancer is highly treatable when detected early, as it carries a favourable prognosis. Therefore, awareness among ...

Darts fans have just a few more hours to enter to win the opportunity to throw nine darts on stage at Alexandra Palace - with ...

Researchers will test the drugs against the disease after finding prostate cancer cells were more likely to duplicate and ...

Clinical data presented at ASCO 2025 showed an objective response rate (ORR) of 63% among all patients, with a median progression-free survival (PFS) of 7.7 months. Responses were seen across ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...